Why Your Term Sheet Shrinks in Due Diligence

A founder signs a term sheet at a stated pre-money valuation. Six weeks later, the investor calls with a lower number, or stops calling.

Nothing about the company changed in those six weeks. What changed is that the investor’s team tested claims the company could not back up.

I help startups build their due diligence systems, and this is the pattern I see most. The founder spent months earning the term sheet and almost no time preparing for what comes after it. What follows about how investors behave comes from my client work.

The term sheet prices a story. Diligence checks it.

A term sheet reflects what the investor believed after your pitch. Diligence is the investor’s team writing down every claim you made and asking what supports it. A gap in that evidence comes in one of three forms, and each needs a different fix.

  • The evidence exists, but nobody can find it. Organizing the files fixes this.
  • The evidence exists, but it does not support the claim. A letter of interest from a department head is real. It does not show who can sign a purchase order. This needs analysis.
  • The work has not been done yet. No file can fix this. It takes customer conversations, a modeled cap table, or contact with buyers.

An investor who finds a gap has to estimate what it might cost. Depending on the gap, the investor may ask a question, add a closing condition, tighten the terms, lower the pre-money, or walk. The estimate moves the price, not the folder structure.

Diligence tests three audiences at once

The investor needs a credible path from your progress to an eventual financial return. That path runs through three kinds of value, judged at the same time, not one after another.

1. Customer Value. Will customers buy, and who signs the check?

2. Investor Value. Can the investor see how milestones reduce risk, and is the company clean enough to own?

3. Acquirer Value. Is there a believable buyer who would want this company later, and do you understand why?

You are pitching one investor. That investor’s diligence tests all three, because a return that comes from a sale depends on all three fitting together.

Progress in one area does not automatically carry over

A milestone that strengthens one audience can leave another unmoved. A revenue number is evidence of demand to you. It may be too small to move a growth investor, and it may be the wrong type of revenue for the buyer who would acquire you.

Take a hospital pilot. It shows clinical interest, which helps the customer case. It helps the investor case more when it establishes a repeatable purchasing process: a named budget owner, a budget line, and a route to the next hospital. It helps the acquirer case when that process matches how a plausible buyer sells and serves hospitals.

A pilot that stops at clinical interest leaves the other two audiences with a question.

Founders tend to prepare these in order: customers first, then the cap table, then buyers. Diligence does not have to read them in order. Counsel can open the cap table in week one while the customer calls are still being scheduled.

Picture a medtech founder holding a signed term sheet. This is an illustration, not a client.

  • Customer Value: A hospital pilot ran for four months. The investor asks who owns the budget to buy after the pilot. The founder has a letter of interest from a department head and no named budget owner.
  • Investor Value: A 2023 convertible note has a valuation cap nobody modeled. The investor’s counsel models it and finds more dilution than the founder’s slide showed.
  • Acquirer Value: The deck says “multiple strategic acquirers.” The investor asks for names and for what each buyer would need to see. The founder has neither.

Each gap gives the investor a reason to ask for a lower price, tighter terms, a closing condition, or more time.

What reduces avoidable surprises

Diligence will still find real weaknesses, and a documented answer can reveal a business reality the investor does not like. The aim is narrower: nothing material should surprise you, and every open question should arrive with your answer and your plan beside it. These are the warning signs I check first.

  • Customer: weak or inconsistent traction, no clear decision maker or budget owner, an unclear distribution channel, a training and implementation burden that is too high, and reimbursement gaps where reimbursement applies.
  • Investor: a vague milestone plan, no link between milestones and the risks they resolve, cap table problems or governance friction, a mismatch with the target fund’s structure, and unrealistic expectations about valuation or timelines.
  • Acquirer: no evidence you know who would buy you and why, generic positioning against likely buyers, no believable story for where the company fits in a buyer’s portfolio, and, at later stages, no strategic conversations in motion.

The acquirer questions carry a second test: can the investor sell the company within the life of the fund? Strong customer numbers do not answer that. If every likely buyer is absorbing another acquisition for the next eighteen months, customer growth alone does not fix the timing. I see founders with the least evidence on this one.

What to build before the term sheet

Write one page per area. For each claim, show the evidence, what it supports, and what remains unresolved.

  • Customer: the named budget owner, the budget line, and the evidence the pilot converts to a purchase.
  • Investor: a table linking each milestone to the risk it resolves and the evidence that could support a higher valuation; the investor’s stage, sector, check size and ownership target matched against your round; and a cap table that models every note, SAFE, and option pool.
  • Acquirer: a list of likely buyers, the reason each would buy, what evidence each would need, and every contact so far with dates.

Where the honest answer is “we do not know yet,” write that down with the date you will know and what result would change it. I find an investor can price a known gap with a date more easily than a gap nobody mentioned.

Then run one test. Hand the pages to someone outside the company. In ten minutes, can they find the evidence for each claim, say what it supports, and name what is still unresolved? If not, expect the investor’s team to hit the same wall.

I would do this before the term sheet. After it, the clock runs on the investor’s schedule, and gaps that need customer or buyer work take longer to close than that schedule allows.

The Bottom Line

Due diligence exposes the distance between what a founder claims and what the business can show. Find that distance before the investor does, close the gaps that matter, and put the rest in writing before the term sheet.

Want to check your own materials against this? Get my due diligence checklist, or get in touch and I will read your diligence materials the way the investor’s team will.

-->